文献速递造血干细胞移植与细胞治疗血栓与止血

成人移植相关血栓性微血管病的临床结局与治疗策略:协调定义与高风险标准的外部验证

Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria.
PubMed 文献 · Am J Hematol · 2025-03-06

该研究在梅奥诊所罗切斯特院区回顾性分析了2005至2022年间99例符合更新版移植相关血栓性微血管病(TA-TMA)协调定义的同种异体造血细胞移植后成人患者,TA-TMA发生率为6.2%。TA-TMA与移植后总生存期较差相关(HR:3.8,95%CI:2.97-4.72),合并感染、急性移植物抗宿主病(GVHD)和器官功能障碍等高风险特征与生存较差相关,而乳酸脱氢酶(LDH)升高与不良结局无关。

要点

  • TA-TMA与移植后总生存期较差相关(HR:3.8,95%CI:2.97-4.72)。
  • 合并感染、急性GVHD和器官功能障碍与生存较差相关,LDH升高与不良结局无关。
  • 停用钙调神经磷酸酶抑制剂或mTOR抑制剂后37.5%患者GVHD加重,其中86.7%死亡。

核心结论

  • TA-TMA仍是异基因造血细胞移植后非复发死亡的重要原因,并与更差的生存相关。
  • 并非所有高风险特征(尤其是LDH升高)在成人队列中均一致显示负面影响。
  • 作者认为TA-TMA患者可能受益于免疫抑制剂量调整而非停药,以及添加补体导向治疗,尤其在高风险患者中。

研究设计与样本

  • 回顾性外部验证研究,纳入2005年至2022年在梅奥诊所罗切斯特院区诊断的99例成人TA-TMA患者(发生率6.2%),诊断距alloHCT中位137天(IQR:34-283天)。

主要发现

  • TA-TMA与移植后总生存期较差相关(HR:3.8,95%CI:2.97-4.72)。
  • 合并感染、急性GVHD和器官功能障碍与生存较差相关,LDH升高与不良结局无关。
  • 最常见的治疗策略是停用钙调神经磷酸酶抑制剂或mTOR抑制剂,共80例(81%);其中30例(37.5%)GVHD加重,这30例中26例(86.7%)末次随访时已死亡。
  • 这些患者最常见死因为GVHD加重(69%;n=18),其次为感染(11%;n=3)、疾病复发(8%;n=2)、其他/未知原因(8%;n=2)或TA-TMA(4%;n=1)。
  • 队列对初始治疗的客观缓解率(ORR)为56.6%;11例使用依库珠单抗,观察到的ORR为70%,包括5例完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high-risk features on the clinical outcomes of adult patients meeting the updated TA-TMA harmonizing criteria. Between 2005 and 2022, 99 patients were diagnosed with TA-TMA at Mayo Clinic Rochester (incidence 6.2%) after a median of 137 days post alloHCT (IQR: 34-283 days). The development of TA-TMA was associated with an inferior overall survival posttransplant (HR: 3.8, 95% CI: 2.97-4.72). High-risk features, including concomitant infection, acute graft-versus-host disease (GVHD), and organ dysfunction, were associated with poor survival, while LDH elevation was not associated with inferior outcomes. The most common treatment strategy for TA-TMA was discontinuation of calcineurin or mTOR inhibitors in 80 (81%) patients. Thirty (37.5%) patients experienced worsening of GVHD with this strategy, of which 26 (86.7%) patients had died at last follow-up. The most common cause of death among these patients was worsening GVHD (69%; n = 18), followed by infection (11%; n = 3), disease relapse (8%; n = 2), other/unknown causes (8%; n = 2), or TA-TMA (4%; n = 1). Objective response rate (ORR) to initial treatment for the cohort was 56.6%. Eculizumab was used in 11 patients with an observed ORR of 70%, including 5 complete responses. In conclusion, TA-TMA remains a significant contributor to non-relapse mortality and is associated with worse survival following alloHCT. Not all high-risk features, particularly LDH elevation, have consistently demonstrated a negative impact in adult cohorts. Patients with TA-TMA may benefit from immune suppression dose adjustment, rather than a discontinuation, and the addition of complement-directed therapy, particularly among high-risk patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Acosta-Medina AA, Sridharan M, Go RS, et al. Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria. Am J Hematol. 2025. PMID: 40047384. doi:10.1002/ajh.27651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。